Latest studies have declared ENBRELR (etanercept) safe to be used to treat psoriasis up to an extended period of two and half years. The result of the current studies were presented at the 15th European Academy of Dermatology and Venereology (EADV)Congress . ENBREL is a 'Biologic Medicine which means it is synthesized using recombinant DNA or rDNA derived protein using current principles of biotechnology.
This biologic medicine acts by inhibiting one of the main mediators which triggers off inflammatory processes. Enbrel happens to be topmost biologic therapeutic clinically approved worldwide, It is also less cumbersome for patients as it is marketed in convenient 25mg and 50mg syringes making it most adaptable for treatment purposes.
Bruce Strober MD PhD, co director of the Psoriasis and Psoriatic Arthritis Center at New York University mentions that that these findings are very significant as it confirms the parameters within which Enbrel is safe to be used, and also provides valuable information regarding the use of other biologic medicines as well in the long run.
In the 48 week Open Label study that was conducted it was clear that ENBREL produced no unpalatable side effects with extended dosages upto2.5 years when compared with randomized Placebo controlled Parent Studies. No further safety signals were identified. These findings support the conclusions derived from previous research done giving ENBREL50mg twice a week in a 96-week study.